Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Gilead Sciences (NASDAQ:GILD) had its price objective lifted by investment analysts at Truist Financial from $145.00 to $152.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective suggests a potential downside of 2.38% from the company’s previous close.

GILD has been the topic of a number of other research reports. Cantor Fitzgerald lifted their target price on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Wells Fargo & Company raised their price objective on Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday. Argus boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Morgan Stanley lifted their target price on shares of Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday. Twenty-five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $144.04.

Gilead Sciences Stock Performance

Gilead Sciences stock traded up $8.48 during trading hours on Wednesday, hitting $155.71. The company had a trading volume of 5,072,874 shares, compared to its average volume of 7,745,895. Gilead Sciences has a one year low of $93.37 and a one year high of $156.88. The firm has a market cap of $193.19 billion, a PE ratio of 24.21, a PEG ratio of 0.80 and a beta of 0.36. The firm has a 50-day moving average of $128.39 and a 200 day moving average of $121.53. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter last year, the business earned $1.90 EPS. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. This represents a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 319,391 shares of company stock worth $44,141,101 in the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

Several large investors have recently added to or reduced their stakes in GILD. GoalVest Advisory LLC grew its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences in the third quarter worth $26,000. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the second quarter worth about $27,000. Ares Financial Consulting LLC bought a new position in Gilead Sciences in the 4th quarter worth about $28,000. Finally, Financial Consulate Inc. raised its holdings in shares of Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 109 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat — Gilead topped top‑ and bottom‑line estimates, driven by strong HIV and liver disease drug sales and early momentum for new product Yeztugo. Analysts highlighted margin strength as well. GILD’s Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms raised PTs and maintained overweight/buy ratings (Morgan Stanley to $171, Needham to $170, Wells Fargo to $165, JPMorgan to $160, Scotiabank to $177), bolstering demand and helping push the stock higher. Morgan Stanley raises price target to $171 Needham maintains Buy, raises PT to $170
• Positive Sentiment: Dividend increase — Board raised the quarterly dividend to $0.82 (3.8% increase), supporting income‑oriented investor interest. Gilead Sciences Announces 3.8-Percent Increase in First Quarter 2026 Dividend
• Neutral Sentiment: Earnings call and materials available — Full Q4 call transcript and slide deck provide detail on product trends, pipeline timing (including potential cancer therapy submissions) for investors doing deeper due diligence. Gilead Q4 2025 Earnings Call Transcript
• Negative Sentiment: Conservative FY2026 guidance — Management set FY26 EPS and revenue guidance at the low end (EPS 8.45–8.85; revenue ~ $29.6–30.0B), below consensus in some estimates, which prompted after‑hours weakness and caution among some investors. Gilead 2026 outlook short of Wall Street view, shares dip Reuters: Gilead quarterly results beat Wall Street estimates

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.